Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:KITE

(KITE) (KITE) Stock Price, News & Analysis

(KITE) logo

About (KITE) Stock (NASDAQ:KITE)

Key Stats

Today's Range
$179.79
$179.79
50-Day Range
N/A
52-Week Range
$39.82
$179.99
Volume
N/A
Average Volume
1.65 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Receive KITE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (KITE) and its competitors with MarketBeat's FREE daily newsletter.

KITE Stock News Headlines

The centerpiece of Trump’s crypto’s masterplan …
Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”
Q3 2024 Kite Realty Group Trust Earnings Call
Former Alabama transfer reportedly dismissed from Auburn team
Kite Realty reports Q3 FFO 51c , consensus 51c
See More Headlines

KITE Stock Analysis - Frequently Asked Questions

(KITE) (NASDAQ:KITE) posted its earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, topping the consensus estimate of ($1.75) by $0.05. The business's revenue was up .0% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that (KITE) investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX) and United Airlines (UAL).

Company Calendar

Last Earnings
2/28/2017
Today
11/06/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:KITE
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:KITE) was last updated on 11/6/2024 by MarketBeat.com Staff
From Our Partners